flonoltinib 50mg

DRUG3 trials

Sponsors

Chengdu Zenitar Biomedical Technology Co., Ltd

Conditions

MF,PMF,PPV-MF,PET-MFMyelofibrosis，MFMyeloproliferative Neoplasm (MPN)

Phase 1

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Chengdu Zenitar Biomedical Technology Co., LtdMyelofibrosis，MF, Myeloproliferative Neoplasm (MPN)

Start: 2021-11-12End: 2023-02-28Target: 31Updated: 2021-11-10

Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

CompletedNCT05153343

Chengdu Zenitar Biomedical Technology Co., LtdMyelofibrosis，MF, Myeloproliferative Neoplasm (MPN)

Start: 2021-12-27End: 2025-03-19Updated: 2025-10-01

Phase 2

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

RecruitingNCT06457425

Chengdu Zenitar Biomedical Technology Co., LtdMF,PMF,PPV-MF,PET-MF

Start: 2024-05-06End: 2026-07-06Target: 75Updated: 2025-04-10

Related Papers

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Blood2025-11-03

First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

Blood2024-11-05